Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Adstiladrin (nadofaragene firadenovec-vncg)
i
Other names:
rAd-IFN/Syn3, SCH 721015/SCH 209702, Ad-IFNalpha/Syn3, rAd-IFN, TR002, FE 999326
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
FKD Therapies, Ferring, Royalty
Drug class:
IFNα stimulant
Related drugs:
‹
pegylated interferon α -2a (3)
interferon alfa 2b (0)
JZP898 (0)
NG-641 (0)
recombinant interferon alfa-2a (0)
SAR441000 (0)
Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 (0)
peginterferon-α-2b (0)
IGN002 (0)
TAK-573 (0)
pegylated interferon α -2a (3)
interferon alfa 2b (0)
JZP898 (0)
NG-641 (0)
recombinant interferon alfa-2a (0)
SAR441000 (0)
Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 (0)
peginterferon-α-2b (0)
IGN002 (0)
TAK-573 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Bladder Cancer
No biomarker
Bladder Cancer
nadofaragene firadenovec-vncg
Sensitive: A1 - Approval
nadofaragene firadenovec-vncg
Sensitive
:
A1
nadofaragene firadenovec-vncg
Sensitive: A1 - Approval
nadofaragene firadenovec-vncg
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login